Effects of chronic exercise and treatment with the antipsychotic drug olanzapine on hippocampal volume in adult female rats

Neuroscience

Volumn 255, Issue , 2013, Pages 147-157

  Barr, A M ^a,b   Wu, C H ^b   Wong, C ^a   Hercher, C ^b   Topfer E ^a   Boyda, H N ^a   Procyshyn, R M ^a,b   Honer, W G ^a,b   Beasley, C L ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health Addiction Services   (Canada)

Author keywords

CA1; Dentate gyrus; Glucose intolerance; Second generation antipsychotic; Stereology

Indexed keywords

OLANZAPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN PERFUSION; BRAIN SIZE; CHRONIC EXERCISE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENTATE GYRUS; DRUG EFFECT; EXERCISE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE; HIPPOCAMPUS; LONG TERM CARE; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL; RAT; SEDENTARY LIFESTYLE;

ANALYSIS OF VARIANCE; ANOVA; AREA-UNDER-THE-CURVE VALUE; AUC; CA1; DENTATE GYRUS; GLUCOSE INTOLERANCE; I.P.; IGTT; INTRAPERITONEAL; INTRAPERITONEAL GLUCOSE TOLERANCE TEST; MAGNETIC RESONANCE IMAGING; MRI; NATIONAL INSTITUTES OF HEALTH; NIH; S.C.; SECOND GENERATION ANTIPSYCHOTIC; SEM; STANDARD ERROR OF THE MEAN; STEREOLOGY; SUBCUTANEOUS;

AGING; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HIPPOCAMPUS; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84887324652     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.10.010     Document Type: Article

References (58)

1. Adriano F., Caltagirone C., Spalletta G. Hippocampal volume reduction in first-episode and chronic schizophrenia: a review and meta-analysis. Neuroscientist 2012, 18:180-200.
2. Barakauskas V.E., Beasley C.L., Barr A.M., Ypsilanti A.R., Li H.Y., Thornton A.E., Wong H., Rosokilja G., Mann J.J., Mancevski B., Jakovski Z., Davceva N., Ilievski B., Dwork A.J., Falkai P., Honer W.G. A novel mechanism and treatment target for presynaptic abnormalities in specific striatal regions in schizophrenia. Neuropsychopharmacology 2010, 35:1226-1238.
3. Barr A.M., Fish K.N., Markou A., Honer W.G. Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. Eur J Neurosci 2008, 27:2568-2574.
4. Barr A.M., Young C.E., Phillips A.G., Honer W.G. Selective effects of typical antipsychotic drugs on SNAP-25 and synaptophysin in the hippocampal trisynaptic pathway. Int J Neuropsychopharmacol 2006, 9:457-463.
5. Barr A.M., Young C.E., Sawada K., Trimble W.S., Phillips A.G., Honer W.G. Abnormalities of presynaptic protein CDCrel-1 in striatum of rats reared in social isolation: relevance to neural connectivity in schizophrenia. Eur J Neurosci 2004, 20:303-307.
6. Bechara R.G., Kelly A.M. Exercise improves object recognition memory and induces BDNF expression and cell proliferation in cognitively enriched rats. Behav Brain Res 2013, 245:96-100.
7. Bekinschtein P., Oomen C.A., Saksida L.M., Bussey T.J. Effects of environmental enrichment and voluntary exercise on neurogenesis, learning and memory, and pattern separation: BDNF as a critical variable?. Semin Cell Dev Biol 2011, 22:536-542.
8. Biedermann S., Fuss J., Zheng L., Sartorius A., Falfan-Melgoza C., Demirakca T., Gass P., Ende G., Weber-Fahr W. In vivo voxel based morphometry: detection of increased hippocampal volume and decreased glutamate levels in exercising mice. Neuroimage 2012, 61:1206-1212.
9. Bonfanti L., Peretto P. Adult neurogenesis in mammals - a theme with many variations. Eur J Neurosci 2011, 34:930-950.
10. Boyda H.N., Procyshyn R.M., Pang C.C., Hawkes E., Wong D., Jin C.H., Honer W.G., Barr A.M. Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine. PLoS One 2013, 8:e53459.
11. Boyda H.N., Procyshyn R.M., Tse L., Hawkes E., Jin C.H., Pang C.C., Honer W.G., Barr A.M. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. J Psychiatry Neurosci 2012, 37:407-415.
12. Boyda H.N., Procyshyn R.M., Tse L., Wong D., Pang C.C., Honer W.G., Barr A.M. Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacology 2012, 62:1391-1400.
13. Boyda H.N., Procyshyn R.M., Tse L., Xu J., Jin C.H., Wong D., Pang C.C., Honer W.G., Barr A.M. Antipsychotic polypharmacy increases metabolic dysregulation in female rats. Exp Clin Psychopharmacol 2013, 21:164-171.
14. Boyda H.N., Ramos-Miguel A., Procyshyn R.M., Topfer E., Lant N., Choy H.H.T., Wong R., Li L., Pang C.C.Y., Honer W.G., Barr A.M. Routine exercise ameliorates the metabolic side-effects of treatment with the atypical antipsychotic drug olanzapine in rats. Int J Neuropsychopharmacol 2013, 1-14.
15. Boyda H.N., Tse L., Procyshyn R.M., Honer W.G., Barr A.M. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 2010, 31:484-497.
16. Boyda H.N., Tse L., Procyshyn R.M., Wong D., Wu T.K., Pang C.C., Barr A.M. A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:945-954.
17. Cherbuin N., Sachdev P., Anstey K.J. Higher normal fasting plasma glucose is associated with hippocampal atrophy: the PATH study. Neurology 2012, 79:1019-1026.
18. Convit A. Links between cognitive impairment in insulin resistance: an explanatory model. Neurobiol Aging 2005, 26(Suppl. 1):31-35.
19. Davey K.J., O'Mahony S.M., Schellekens H., O'Sullivan O., Bienenstock J., Cotter P.D., Dinan T.G., Cryan J.F. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 2012, 221:155-169.
20. Dorph-Petersen K.A., Lewis D.A. Stereological approaches to identifying neuropathology in psychosis. Biol Psychiatry 2011, 69:113-126.
21. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30:1649-1661.
22. Eack S.M., Hogarty G.E., Cho R.Y., Prasad K.M., Greenwald D.P., Hogarty S.S., Keshavan M.S. Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial. Arch Gen Psychiatry 2010, 67:674-682.
23. Ebdrup B.H., Skimminge A., Rasmussen H., Aggernaes B., Oranje B., Lublin H., Baare W., Glenthoj B. Progressive striatal and hippocampal volume loss in initially antipsychotic-naive, first-episode schizophrenia patients treated with quetiapine: relationship to dose and symptoms. Int J Neuropsychopharmacol 2011, 14:69-82.
24. Falkai P., Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci 1986, 236:154-161.
25. Fuss J., Ben Abdallah N.M., Vogt M.A., Touma C., Pacifici P.G., Palme R., Witzemann V., Hellweg R., Gass P. Voluntary exercise induces anxiety-like behavior in adult C57BL/6J mice correlating with hippocampal neurogenesis. Hippocampus 2010, 20:364-376.
26. Gil-Mohapel J., Simpson J.M., Titterness A.K., Christie B.R. Characterization of the neurogenesis quiescent zone in the rodent brain: effects of age and exercise. Eur J Neurosci 2010, 31:797-807.
27. Gold S.M., Dziobek I., Sweat V., Tirsi A., Rogers K., Bruehl H., Tsui W., Richardson S., Javier E., Convit A. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50:711-719.
28. Green W., Patil P., Marsden C.A., Bennett G.W., Wigmore P.M. Treatment with olanzapine increases cell proliferation in the subventricular zone and prefrontal cortex. Brain Res 2006, 1070:242-245.
29. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J Microsc 1987, 147:229-263.
30. Gundersen H.J., Jensen E.B., Kieu K., Nielsen J. The efficiency of systematic sampling in stereology - reconsidered. J Microsc 1999, 193:199-211.
31. Heckers S., Konradi C. Hippocampal pathology in schizophrenia. Curr Top Behav Neurosci 2010, 4:529-553.
32. Hempel R., Onopa R., Convit A. Type 2 diabetes affects hippocampus volume differentially in men and women. Diabetes Metab Res Rev 2012, 28:76-83.
33. Henseler I., Falkai P., Gruber O. Disturbed functional connectivity within brain networks subserving domain-specific subcomponents of working memory in schizophrenia: relation to performance and clinical symptoms. J Psychiatr Res 2010, 44:364-372.
34. Herold C.J., Lasser M.M., Schmid L.A., Seidl U., Kong L., Fellhauer I., Thomann P.A., Essig M., Schroder J. Hippocampal volume reduction and autobiographical memory deficits in chronic schizophrenia. Psychiatry Res 2013, 211:189-194.
35. Hui J.J., Zhang Z.J., Liu S.S., Xi G.J., Zhang X.R., Teng G.J., Chan K.C., Wu E.X., Nie B.B., Shan B.C., Li L.J., Reynolds G.P. Hippocampal neurochemistry is involved in the behavioural effects of neonatal maternal separation and their reversal by post-weaning environmental enrichment: a magnetic resonance study. Behav Brain Res 2011, 217:122-127.
36. Kjonigsen L.J., Leergaard T.B., Witter M.P., Bjaalie J.G. Digital atlas of anatomical subdivisions and boundaries of the rat hippocampal region. Front Neuroinform 2011, 5:2.
37. Kodama M., Fujioka T., Duman R.S. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004, 56:570-580.
38. Koolschijn P.C., van Haren N.E., Cahn W., Schnack H.G., Janssen J., Klumpers F., Hulshoff Pol H.E., Kahn R.S. Hippocampal volume change in schizophrenia. J Clin Psychiatry 2010, 71:737-744.
39. Landers M.R., Kinney J.W., Allen D.N., van Breukelen F. A comparison of voluntary and forced exercise in protecting against behavioral asymmetry in a juvenile hemiparkinsonian rat model. Behav Brain Res 2013, 248:121-128.
40. Letourneau G., Bentaleb L.A., Stip B., Luck D., Stip E. Relationships between brain structure and metabolic changes in schizophrenia patients treated with olanzapine: a voxel-based morphometric study. Schizophr Res Treat 2011, 2011:862350.
41. Leung J.Y., Barr A.M., Procyshyn R.M., Honer W.G., Pang C.C. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012, 135:113-122.
42. Narr K.L., Thompson P.M., Szeszko P., Robinson D., Jang S., Woods R.P., Kim S., Hayashi K.M., Asunction D., Toga A.W., Bilder R.M. Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage 2004, 21:1563-1575.
43. Pajonk F.G., Wobrock T., Gruber O., Scherk H., Berner D., Kaizl I., Kierer A., Muller S., Oest M., Meyer T., Backens M., Schneider-Axmann T., Thornton A.E., Honer W.G., Falkai P. Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 2010, 67:133-143.
44. Panenka W.J., Khorram B., Barr A.M., Smith G.N., Lang D.J., Kopala L.C., Vandorpe R.A., Honer W.G. A longitudinal study on the effects of typical versus atypical antipsychotic drugs on hippocampal volume in schizophrenia. Schizophr Res 2007, 94:288-292.
45. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, Sydney.
46. Sawada K., Barr A.M., Nakamura M., Arima K., Young C.E., Dwork A.J., Falkai P., Phillips A.G., Honer W.G. Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch Gen Psychiatry 2005, 62:263-272.
47. Scheewe T.W., van Haren N.E., Sarkisyan G., Schnack H.G., Brouwer R.M., de Glint M., Hulshoff Pol H.E., Backx F.J., Kahn R.S., Cahn W. Exercise therapy, cardiorespiratory fitness and their effect on brain volumes: a randomised controlled trial in patients with schizophrenia and healthy controls. Eur Neuropsychopharmacol 2013, 23:675-685.
48. Schobel S.A., Lewandowski N.M., Corcoran C.M., Moore H., Brown T., Malaspina D., Small S.A. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch Gen Psychiatry 2009, 66:938-946.
49. Snyder J.S., Radik R., Wojtowicz J.M., Cameron H.A. Anatomical gradients of adult neurogenesis and activity: young neurons in the ventral dentate gyrus are activated by water maze training. Hippocampus 2009, 19:360-370.
50. Tamminga C.A., Stan A.D., Wagner A.D. The hippocampal formation in schizophrenia. Am J Psychiatry 2010, 167:1178-1193.
51. Tomassoni D., Bellagamba G., Postacchini D., Venarucci D., Amenta F. Cerebrovascular and brain microanatomy in spontaneously hypertensive rats with streptozotocin-induced diabetes. Clin Exp Hypertens 2004, 26:305-321.
52. Toulopoulou T., Grech A., Morris R.G., Schulze K., McDonald C., Chapple B., Rabe-Hesketh S., Murray R.M. The relationship between volumetric brain changes and cognitive function: a family study on schizophrenia. Biol Psychiatry 2004, 56:447-453.
53. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biol Psychiatry 2010, 69:936-944.
54. Walter A., Studerus E., Smieskova R., Kuster P., Aston J., Lang U.E., Radue E.W., Riecher-Rossler A., Borgwardt S. Hippocampal volume in subjects at high risk of psychosis: a longitudinal MRI study. Schizophr Res 2012, 142:217-222.
55. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29:1230-1238.
56. Weston-Green K., Huang X.F., Deng C. Sensitivity of the female rat to olanzapine-induced weight gain - far from the clinic?. Schizophr Res 2010, 116:299-300.
57. Wojtowicz J.M., Askew M.L., Winocur G. The effects of running and of inhibiting adult neurogenesis on learning and memory in rats. Eur J Neurosci 2008, 27:1494-1502.
58. Zierhut K.C., Grassmann R., Kaufmann J., Steiner J., Bogerts B., Schiltz K. Hippocampal CA1 deformity is related to symptom severity and antipsychotic dosage in schizophrenia. Brain 2013, 136:804-814.